Isofol Medical AB (publ) (ISOFOL.ST)
Isofol Medical AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Gothenburg, VG, SE. The stock last traded at $0.80, down 0.12% on the session, giving a market capitalisation of $256.7M. Its beta of 1.02 implies it has historically moved more than the broad market.
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Isofol Medical AB (publ) is most often compared with the following Healthcare names: